On April 27, 2019, the SEC filed a complaint in the United States District Court for the Southern District of New York against AbbVie, Inc. ("AbbVie"), alleging that AbbVie violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  The complaint alleges that AbbVie violated Section 17(a) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and that AbbVie violated Section 10(b) of the Exchange Act.  The complaint further alleges that AbbVie violated Rule 10b-5 thereunder.  In a parallel action, the U.S. Attorney's Office for the Southern District of New York today announced criminal charges against AbbVie.  The SEC's complaint, filed in federal court in New York, charges AbbVie with violations of Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act of 1940 ("Advisers Act") and Rule 206(4)-8 thereunder.  Without admitting or denying the allegations in the complaint, AbbVie has consented to the entry of a final judgment that permanently enjoins it from violating Section 10(b) of the Exchange Act as well as Rule 10b-5 thereunder.  Without admitting or denying the SEC's allegations, AbbVie has agreed to the entry of a final judgment permanently enjoining it from violating the antifraud provisions of Section 10(b) and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's investigation, which is continuing, is being conducted by Terence Flynn and supervised by Peter Diskin. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.